Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ImmuneNet: Quantum-Synaptic Immunotherapy Mapping

NCT07221565 is registered in ClinicalTrials.gov with Truway Health, Inc. as lead sponsor.

NCT NCT07221565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ImmuneNet: Quantum-Synaptic Immunotherapy Mapping
Lead sponsor
Truway Health, Inc.
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
October 23, 2025
Completion date
October 23, 2034
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, chronic inflammatory syndromes, immune dysregulation, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus